Table 3.
Recent preclinical studies using hyperthermia and thermosensitive liposomes.
| Thermosensitive Liposomes | |||||
|---|---|---|---|---|---|
| Composition | HT | Drug | Target | Response | Ref. |
| DPPC/DSPC/DSPE–PEG2000 70/25/5 |
Water bath | DOX | Breast cancer | Significant increase in tumor response to liposome and HT treatment | [103] |
| DPPC/DSPC/DPPG2 50/20/30 | Laser light | DOX | Soft tissue sarcoma | High selective DOX uptake and increase of DOX concentration in the heated tumor tissue | [101] |
| DPPC/DSPC/DPPG2 50/20/30 | Laser light | DOX | Soft tissue sarcoma | Effective DOX delivery by liposome found in the heated tumors in comparison with the non-heated tumors | [102] |
| DPPC/DSPC/DPPG2 50/20/30 | HIFU | Gemcitabine | Soft tissue sarcoma | Significant improvement in tumor growth delay | [100] |
| DPPC/MSPC/DSPE–PEG2000/DSPG 83/3/10/4 |
Water bath | Paclitaxel | Lung cancer | Tumor growth suppression, compared with non-temperature-sensitive liposome and free drug | [82] |
HT: Hyperthermia; DPPC: 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine; DSPC: 1,2-Distearoyl-sn-glycero-3-phosphocholine; DSPE: 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine; DPPG2: 1,2-Dipalmitoyl-sn-glycero-3-phospho-rac-glycerol; MSPC: 1-Myristoyl-2-stearoyl-sn-glycero-3–phosphocholine; PEG: Polyethylene glycol.